Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib in relapsed/refractory non-GCB DLBCL
NCT05319028Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mivavotinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Calithera Biosciences. Started Jun 2022; status: terminated.
02
Drugs
mivavotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05319028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319028.